[Uremic hemolytic syndrome induced by mitomycin C. Presentation of a series of 5 cases and review of the literature].
Five new cases of hemolytic uremic syndrome associated mitomycin C treatment in neoplastic patients are presented and clinical, biological, histological therapeutic and the evolution data of 92 other cases from the literature are analyzed. The results point out the high incidence of GI adenocarcinomas (65%), its rare appearance with total mitomycin doses below 50 mg/m2, its frequent clinical presentation with cardiovascular manifestations, the therapeutical difficulties and the possibility of a better prognosis with an early diagnosis.
Nicolás
J M
JM
Servei de Medicina Interna General, Hospital Clinic, Universitat de Barcelona.
Villalta
J
J
González-Clemente
J M
JM
Antúnez
E
E
Almirall
J
J
Bosch
J
J
Torras
A
A
Urbano-Márquez
A
A
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects* / Q000627:therapeutic use; D013030:Spain
D008937:Mitomycins; D016685:Mitomycin
Síndrome hemolítico urémico inducido por mitomicina C. Presentación de una serie de cinco casos y revisión de la literatura.